Related references
Note: Only part of the references are listed.Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion
Adrian Tempescul et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
New perspectives on complement mediated immunotherapy
Grzegorz Stasilojc et al.
CANCER TREATMENT REVIEWS (2016)
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Di Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
Erika M. Cook et al.
JOURNAL OF IMMUNOLOGY (2016)
Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
Guanbo Wang et al.
MOLECULAR CELL (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor et al.
SEMINARS IN IMMUNOLOGY (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells
Stefanie Derer et al.
JOURNAL OF IMMUNOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Complement in therapy and disease Regulating the complement system with antibody-based therapeutics
Joost P. M. Melis et al.
MOLECULAR IMMUNOLOGY (2015)
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop
Thies Rosner et al.
JOURNAL OF IMMUNOLOGY (2014)
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer et al.
MABS (2014)
A simple, robust and highly efficient transient expression system for producing antibodies
Tom Vink et al.
METHODS (2014)
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Christian Kellner et al.
METHODS (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Antibody-Based Immunotherapy of Cancer
Louis M. Weiner et al.
CELL (2012)
Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies
Stefanie Derer et al.
JOURNAL OF IMMUNOLOGY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)
Katja Klausz et al.
CANCER SCIENCE (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Yi-Fan Hsu et al.
MOLECULAR CANCER (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization
Judith Schmiedel et al.
CANCER CELL (2008)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Effector mechanisms of therapeutic antibodies against ErbB receptors
Matthias Peipp et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Structure and clinical relevance of the epidermal growth factor receptor in human cancer
Amit Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
RM Perera et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
WK Bleeker et al.
JOURNAL OF IMMUNOLOGY (2004)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Convergent solutions to binding at a protein-protein interface
WL DeLano et al.
SCIENCE (2000)
Share Paper
